NASDAQ: GNLXGenelux Corp Stock
$3.03+0.01 (+0.33%)
Updated Jun 16, 2026
GNLX Price
$3.03
Fair Value Price
$0.10
Market Cap
$135.87M
52 Week Low
$2.29
52 Week High
$8.54
P/E
-3.56x
P/B
5.93x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$33.58M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.41
Operating Cash Flow
-$26M
Beta
1.45
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GNLX Overview
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GNLX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GNLX
Ranked#355 of 462
Ranked#355 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important GNLX news, forecast changes, insider trades & much more!
GNLX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GNLX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GNLX ($3.03) is overvalued by 2,998.54% relative to our estimate of its Fair Value price of $0.10 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GNLX ($3.03) is not significantly undervalued (2,998.54%) relative to our estimate of its Fair Value price of $0.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GNLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GNLX due diligence checks available for Premium users.
Valuation
GNLX fair value
Fair Value of GNLX stock based on Discounted Cash Flow (DCF)
Price
$3.03
Fair Value
$0.10
Overvalued by
2,998.54%
GNLX ($3.03) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GNLX ($3.03) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GNLX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GNLX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.56x
Industry
16.03x
Market
13.25x
GNLX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.93x
Industry
4.86x
GNLX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GNLX's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.9M
Profit Margin
0%
GNLX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$32.4M
Liabilities
$9.5M
Debt to equity
0.41
GNLX's short-term assets ($26.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GNLX's short-term assets ($26.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GNLX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
-$8.5M
Financing
$18.5M
GNLX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GNLX vs Biotech Stocks
Genelux Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.